



Wayne Macfadden MD

US Medical Director, *Seroquel*
 AstraZeneca LTD
 Wilmington, Delaware
 Email: wayne.macfadden@astrazeneca.com

Credentials	Licensure Diplomate	New Jersey National Board of Medical Examiners National Board of Psychiatry and Neurology- 1989 Added Qualifications in Addiction Psychiatry- 1991
Education	MD BS	State University of New York at Buffalo School of Medicine, 1985 City College of New York, Biomedical Science, 1983
Training		University of Pennsylvania, Philadelphia, PA Resident in Psychiatry, 1986-89 Millard Fillmore Hospital, Buffalo, NY Internal Medicine Resident, 1985-86

Pharmaceutical Industry

Associate Director, Worldwide Clinical Safety
 SmithKline Beecham Pharmaceuticals
 Collegeville, PA 1999- 2000

Associate Director, North American Medical Affairs, CNS
 GlaxoSmithKline Pharmaceuticals
 Collegeville, PA 2000- 2001

Director, Clinical Research, CNS Therapeutic Area
 AstraZeneca Pharmaceuticals
 Wilmington, DE 2001- 4

Senior Director, Clinical Research, and
 US Medical Director, *Seroquel*
 AstraZeneca Pharmaceuticals
 Wilmington, DE January 2004- present

Committees Institutional Review Board (IRB), Memorial Hospital of Burlington County, 1998
Human Subjects Subcommittee (IRB), Philadelphia VAMC, 1997-98
Public Relations Committee, Philadelphia Psychiatric Society, 1990-92
Residency Training and Education Committee, 1988-89

Instruction PGY II residents, Department of Psychiatry, University of Pennsylvania
Medical students – Psychiatry 200A, University of Pennsylvania School of Medicine
Postgraduate Fellows, Department of Psychiatry, Substance Abuse Research Fellowship,
University of Pennsylvania School of Medicine 1990-98

Appointments

Faculty

Clinical Assistant Professor of Psychiatry
University of Pennsylvania, Philadelphia, PA, 1991-99

Clinical Associate Department of Psychiatry
University of Pennsylvania, 1989-91

Assistant Clinical Instructor of Psychiatry
University of Pennsylvania, 1986-89

Assistant Clinical Instructor of Medicine
State University of New York, Buffalo School of Medicine, 1985-86

Hospital and Administrative

Director
Substance Abuse Treatment Services
Virtua Health System, NJ, 1998-9

Chief
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
Inpatient Dual Diagnosis Unit, 1996-98
Inpatient Detoxification Unit, 1993-96

Wayne Macfadden MD

Associate Clinical Director

Modern Psychiatric Systems (DeltaMetrics), Philadelphia, PA, 1995-96

Staff Psychiatrist

Philadelphia Veterans Affairs Medical Center, 1990-93
Inpatient Psychiatry, Outpatient Drug Treatment

Neuman Medical Center, Philadelphia, PA 1990-93
Inpatient Psychiatric Units

Mercy Catholic Medical Center, Philadelphia, PA 1989-90
Inpatient Psychiatry and Detoxification

Philadelphia Child Guidance Clinic, Philadelphia, PA 1989

Psychiatric House Physician

Lower Bucks Hospital, Bristol, PA, 1988-89
Allentown State Hospital, Allentown, PA 1987-88.

Participation in Industry Sponsored trials

Pharmacia/Upjohn

Study of CDTest, an enzyme immunoassay for quantitative measurement of carbohydrate deficient transferrin in human serum, as a tool for monitoring abstinence and relapse in patients treated for alcohol abuse and dependence. Multicenter, 1998. (Subinvestigator)

Schering

Effects of XXXX on the physiological effects and pharmacokinetics of intravenous cocaine: A placebo control, rising single dose interaction study. Multicenter, 1997. (Subinvestigator)

Burroughs/Wellcome

XXXX for treatment of cocaine dependence in methadone-maintained patients. Multicenter, 1992 (Subinvestigator)

Wayne Macfadden MD

NIDA (National Institute of Drug Abuse)

A safety evaluation of the interaction of piracetam and cocaine in cocaine dependent patients 1996 (Subinvestigator)

NIDA

Dextromethorphan in methadone-maintained patients 1997 (Subinvestigator)

- Publications Macfadden W., Cannabis Related Disorders. Francis A., Chairperson. Diagnostic And Statistical Manual of Mental Disorders 4th Edition. APA Press, Washington, DC 1994.
- Macfadden W., Woody G.E. Cannabis. Kaplan H.I., Sadock B.J. (eds). Comprehensive Textbook of Psychiatry 7th Edition. Williams and Wilkins Company, Baltimore 1998.
- Macfadden W., Woody G.E. Cannabis. Kaplan H.I., Sadock B.J. (eds). Comprehensive Textbook of Psychiatry 6th Edition. Williams and Wilkins Company, Baltimore 1994.
- Caroff S.N., Macfadden W., Mann S.C., Sullivan K. Drug induced hypermetabolic syndromes. Ohnishi T. (ed). Malignant Hyperthermia - A Membrane Linked Disease. Taylor & Francis, New York (in press).
- Caroff S.N., Macfadden W., Mann S.C., Sullivan K. NMS: Diagnostic issues. Psychiatric Annals 21: 165-174, 1991
- Auricombe M., Macfadden W., Mann S.C. Lethal catatonia: Clinical aspects and therapeutics: A literature review. Encephale. 2001 May-Jun;27(3):213-6.
- Fudala P.J., Yu E., Macfadden W. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug and Alcohol Depend. 1998 Mar 1;50(1):1-8.
- A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression. Joseph R. Calabrese, M.D. Paul E. Keck, Jr., M.D. Wayne Macfadden, M.D. et al. Am J Psych, 162:7, July 2005, p 1351- 1360

Wayne Macfadden MD

Quetiapine for the treatment of Bipolar II depression: A Randomized, double-blind, placebo controlled study Suppes T, Vieta E, Hirschfeld RM, Raines S, Macfadden W. J Clinical Psychiatry (In press)

Quetiapine Effects on Anxiety Symptoms in Patients With Bipolar Depression: Randomized, Double-Blind, Placebo-Controlled Study. Hirschfeld RM, Weisler R, Macfadden W. J Clin Psych, 67:3, March 2006.

Quetiapine monotherapy in the treatment of patients with rapid-cycling bipolar I or II depression: A Randomized, Double-Blind, Placebo-Controlled study. Vieta, E., Calabrese JR, Goikolea JM, Raines S, Macfadden W. Biological Psychiatry (In press)

Letters to the editor

Macfadden W., Maany I. et al. Methadone and edema. J Clin Psychiatry. 1990 Jan;51(1):36-7.

Geller WK, Macfadden W. Diabetes and atypical neuroleptics. Am J Psychiatry. 2003 Feb; 160 (2):388.

Goldstein J, Macfadden W. Tolerance and rebound during maintenance with quetiapine. J Clin Psychopharmacol. 2004 Feb;24(1):102-3.

Presentations

"Hepatitis B & C on an Addiction Treatment Unit." Dhopes V.D., Macfadden W., et al. American Psychiatric Association Annual Meeting, (Toronto, Canada.) June 2, 1998.

"An Open Label Pilot Safety Study of Lofexidine for the Treatment of Opiate Withdrawal." Yu E., Herman B.H., Fudala P.J., Ling W., Macfadden W. College on the Problems of Drug Dependence, 59th Annual Scientific Meeting, Nashville, TN. June 16, 1997.

"Factors Affecting Length of Stay on an Inpatient Detox Unit." Macfadden W. College on the Problems of Drug Dependence, 58th Annual Scientific Meeting, San Juan, Puerto Rico. June 25, 1996.

Wayne Macfadden MD

"Electroconvulsive Therapy in the Treatment of Lethal Catatonia." University of Bordeaux School of Medicine, Conference for the study of ECT, Bordeaux, France, October 12, 1992

Anti-Anxiety Effects Analysis of Quetiapine in Bipolar Depression
Macfadden W, Calabrese J, McCoy R, et al. American Psychiatric Association (New York, NY) May 4, 2004

Double-Blind, Placebo-Controlled Study of Quetiapine in Bipolar Depression
Calabrese J, Macfadden W, McCoy R, et al. American Psychiatric Association (New York, NY) May 4, 2004

Double-Blind, Placebo-Controlled Study of Quetiapine in Bipolar I Depression
Macfadden W, Calabrese J, McCoy R, Minkwitz M, Wilson E, Mullen J. CINP 04 – Collegium Internationale Neuro-Psychopharmacologium (Paris, France) June 22, 2004

Quetiapine for the Treatment of Rapid-Cycling Bipolar Depression
Vieta E, Calabrese J, Macfadden W, Minkwitz M, Mullen J. Stanley 04 – European Stanley Conference on Bipolar Disorders (Aarhus, Denmark) September 24, 2004

Quetiapine in Bipolar Depression: Time-to-Event Analyses
Keck P, Ketter T, Macfadden W, Minkwitz M, Mullen J. Stanley 04 – European Stanley Conference on Bipolar Disorders (Aarhus, Denmark) September 24, 2004

"Comparison of Treatments for Bipolar Depression" (Scientific Session) Canadian Psychiatric Association (Montreal, Canada) October 7, 2004

Efficacy of Quetiapine in Improving Quality of Life in Patients with Bipolar Depression
Endicott J, Rajagopalan K, Macfadden W, et al. AEP 05 – Association of European Psychiatrists (Munich, Germany) April 3, 2005

Efficacy of Quetiapine Monotherapy in Bipolar Depression: A Confirmatory double-blind, placebo-controlled study (The BOLDER II Study) Thase M, Macfadden W, McCoy R. American Psychiatric Association Annual Meeting, (Toronto, Canada) May, 2006

Wayne Macfadden MD

Efficacy of Quetiapine Monotherapy in Bipolar I Depression: combined results from two Double-Blind, Placebo-Controlled Studies. Weisler R, Arvekvist J, Stening G, Macfadden W. American Psychiatric Association Annual Meeting, (Toronto, Canada) May, 2006

Improvement in anxiety symptoms in Bipolar Depression with Quetiapine Monotherapy: results from two placebo-controlled studies. Lydiard B, Culpepper J, Raincs S, Macfadden W. American Psychiatric Association Annual Meeting, (Toronto, Canada) May, 2006

Quetiapine Monotherapy Demonstrates Efficacy in Reducing Suicidality in Bipolar Depression. Macfadden W, Minkwitz M, Spong E. American Psychiatric Association Annual Meeting, (Toronto, Canada) May, 2006

Quetiapine Monotherapy for Bipolar II depression: pooled results from two placebo-controlled studies. Suppes T, Hirschfeld RM, Vieta E, Carlsson J, Stening G, Macfadden W. American Psychiatric Association Annual Meeting, (Toronto, Canada) May, 2006